Clinical outcomes and molecular characteristics of patients with pancreatic acinar cell carcinoma.
Cody Eslinger(WinnMed), Bassam Bassam Sonbol(WinnMed), Jason S. Starr(Jacksonville College), Rish K. Pai(Cincinnati Children's Hospital Medical Center), Christopher Hartley(Mayo Clinic in Arizona), Tanios Bekaii‐Saab(AstraZeneca (United Kingdom)), Zaid Elsabbagh(Apple (Israel)), Claire Yee(Mayo Clinic in Florida), Þorvarður R. Hálfdánarson(Mayo Clinic), Bobak Seddighzadeh(WinnMed)
Cited by 1
Related Papers
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
|JAMA Oncology|2019|472
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
|The Lancet. Gastroenterology & hepatology|2021|423
Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors
|Endocrine Related Cancer|2008|374